Globally, 49 million people suffer from sepsis each year. This leads to 11 millions deaths, which equates to 20% of deaths around the world.
Rapid detection for sepsis is crucial. Every hour this disease goes untreated, the chances of mortality go up by 8%.
To learn more about the disease, the difficulties of diagnosis and the importance of rapid detection; we sat down with Stefan Willemsen, former President and CEO of the US subsidiary of bioMerieux and board member of Sepsis Alliance.
We also spoke to Jonathon Romanowsky, co-founder of Inflammatix - who are one of the most innovative start-ups working within sepsis right now, applying bioinformatics and machine learning to their test.
Our latest video on liquid biopsy, featuring Business Development Consultant in Oncology and Liquid Biopsy, Dale Yuzuki, is also available to watch now.
If you found this video interesting and would like to talk to us more about the innovations you've seen in diagnostics, please contacts us via email at Eleanor.Doolin@lifesci-cm.com or Adam.Hargreaves@lifesci-cm.com.
You can find more of Eleanor's content on her consultant page.
You can find more of Adam's content on his consultant page.
Adam Hargreaves
Adam Hargreaves is Principal Consultant specialising within commercial IVD, covering a global market. Adam is a specialist at building teams and making sure new hires culturally align to company goals. Fascinated by his market, Adam is always keen to talk with experts and leading executives on the subjects that matter most to you.
Eleanor Doolin
Eleanor Doolin works as an Associate Director working broadly within IVD but has previously spent time focusing specifically in clinical chemistry and oncology, plus advances in non-invasive diagnostic testing. She is always looking to connect with innovative individuals and organisations working in this area.
Comments.